The civic record
Read. Follow. Verify.American Biotechnology Competitiveness Act (SA 6334)
Record date · June 24, 2026
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
This amendment proposes a national strategy to secure U.S. biotechnology leadership by regulating , establishing a cloud-based laboratory network, and creating a national biopharmaceutical manufacturing center. It aims to mitigate biosecurity risks from synthetic pathogens while boosting domestic manufacturing and research capabilities.
This legislation would create new federal oversight for companies that synthesize DNA, establish a $150 million cloud-based research network, and authorize $120 million for a new biopharmaceutical manufacturing center to reduce reliance on foreign supply chains.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
Synthetic nucleic acid providers
Must implement new screening protocols for orders and customers and undergo mandatory conformity assessments.
Biopharmaceutical manufacturers
May access the new Innovation Center for research, workforce training, and infrastructure support.
Institutions of higher education
Eligible to apply for designation as nodes in the cloud laboratory network and participate in biomanufacturing research.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What is a 'covered provider' under this act?
How will the government ensure my data remains private?
What is a 'programmable cloud laboratory'?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceFull breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Shift toward automated biosecurity
The bill explicitly moves away from voluntary guidelines toward mandatory, federally-enforced screening protocols for DNA synthesis, signaling a major shift in biosecurity policy.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools